The AP1 Transcription Factor Fosl2 Promotes Systemic Autoimmunity and Inflammation by Repressing Treg Development.
Animals
Autoimmunity
Bone Marrow
/ pathology
DNA-Binding Proteins
/ metabolism
Encephalomyelitis, Autoimmune, Experimental
/ immunology
Forkhead Transcription Factors
/ metabolism
Fos-Related Antigen-2
/ metabolism
Gene Deletion
Inflammation
/ immunology
Mice, Inbred C57BL
Phenotype
Receptors, Antigen, T-Cell
/ metabolism
T-Lymphocytes, Regulatory
/ immunology
Transcription Factor AP-1
/ metabolism
FoxP3
T cells
autoimmunity
immunology
inflammation
mouse models
regulatory T cells
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
30 06 2020
30 06 2020
Historique:
received:
14
10
2019
revised:
27
03
2020
accepted:
05
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
29
4
2021
Statut:
ppublish
Résumé
Regulatory T cells (Tregs) represent a major population in the control of immune homeostasis and autoimmunity. Here we show that Fos-like 2 (Fosl2), a TCR-induced AP1 transcription factor, represses Treg development and controls autoimmunity. Mice overexpressing Fosl2 (Fosl2
Identifiants
pubmed: 32610127
pii: S2211-1247(20)30807-X
doi: 10.1016/j.celrep.2020.107826
pii:
doi:
Substances chimiques
DNA-Binding Proteins
0
Forkhead Transcription Factors
0
Fos-Related Antigen-2
0
Fosl2 protein, mouse
0
Foxp3 protein, mouse
0
Rag2 protein, mouse
0
Receptors, Antigen, T-Cell
0
Transcription Factor AP-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107826Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests O.D. had consultancy relationships and/or has received research funding from A. Menarini, Acceleron Pharma, Amgen, AnaMar, Bayer, Boehringer Ingelheim, Catenion, CSL Behring, ChemomAb, Ergonex, GSK, Inventiva, Italfarmaco, iQone, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, Merck Sharpe & Dohme (MSD), Novartis, Pfizer, Roche, Sanofi, Blade Therapeutics, CSL Behrings Target Bio Science, and UCB in the area of potential treatments for scleroderma and its complications. In addition, Prof. Distler has a patent mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143). R.H. and A.S. are full-time employees of Sanofi-Genzyme.